OQROGet OQRO Pro
Politician trade (House)

Boston Scientific (BSX)Rep. Kevin Hern (OK01) disclosed a sale $50K–$100K

Rep. Kevin Hern (OK01) disclosed a sale of Boston Scientific in the $50K–$100K range.

$50,001–$100,000
Reported range · official band, not an exact amount
16 days
Disclosure lag
Traded
Sep 9, 2026
Disclosed
Sep 25, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 24, 2026FDAFDA device clearance: TheraSphere 360™ Y-90 Management Platform
  2. Jul 24, 2026FDAFDA device clearance: OBSIDIO Conformable Embolic
  3. Jul 24, 2026FDAFDA device clearance: FARADRIVE™ Steerable Sheath (M004PF21M402)
  4. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
  5. Jul 31, 2026InsiderDirector purchased ~$227K of BSX shares in the open market
  6. Aug 3, 2026Insider · 2 peopleInsiders: 2 purchases (~$9.1M)
  7. Aug 4, 2026FDAFDA device clearance: Navigator™ Flex Ureteral Access Sheath Set
  8. Aug 4, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$6.8K of BSX shares in the open market
  9. Aug 5, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$100K of BSX shares in the open market
  10. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS US, Model Number 7260, All Versions (Current 7.8)
  11. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS ANZ, Model Number 7248, All Versions (Current 7.7)
  12. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS EU, Model Number 7246, All Versions (Current 7.7)
  13. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 3.1%
  14. Aug 12, 2026FDAFDA device clearance: EluPro Antibiotic-Eluting BioEnvelope
  15. Aug 18, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  16. Aug 21, 2026FDAFDA device clearance: AVVIGO™+ Multi-Modality Guidance System
  17. Aug 24, 2026FDARecall: Imager II Angiographic Catheters M001314001 IMAGER II/5/ST/65/038 BX5; M001314011 IMAGER II/5/ST/100/038 BX5; M001314021 IMAGER II/5/ST/65/035 BX 5; M001314031…
  18. Aug 25, 2026Insider · 13 days before an 8-KDirector purchased ~$100K of BSX shares in the open market
  19. Aug 26, 2026FDAFDA device clearance: LithoVue Elite Digital Flexible Ureteroscope System
  20. Aug 31, 2026CongressDisclosed sale of BSX — reported range $15,001 - $50,000
  21. Sep 3, 2026FDAFDA device clearance: Rezum System
  22. Sep 3, 2026Congress · 1 personMembers of Congress: 3 sales
  23. Sep 4, 2026CongressDisclosed partial sale of BSX — reported range $50,001 - $100,000
  24. Sep 7, 2026Company filing · Form 8-K · Cyber incidentReported a cybersecurity incident“As previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation (the “ Company ”) identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global disruption to the Company’s operations.”
  25. Sep 9, 2026 · this disclosureCongressDisclosed sale of BSX — reported range $50,001 - $100,000

What came next

  1. Sep 11, 2026FDAFDA device clearance: SpaceOAR Flex™ System
  2. Sep 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.”
  3. Oct 1, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.”
  4. Oct 1, 2026Federal contract · $465K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $465K obligated to date
  5. Oct 1, 2026Federal contract · $524K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $524K obligated to date
  6. Oct 1, 2026Federal contract · $832K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $832K obligated to date
  7. Oct 1, 2026Federal contract · $880K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $880K obligated to date
  8. Oct 1, 2026Federal contract · $1.0M obligatedDepartment of Veterans Affairs awarded Boston Scientific: $1.05M obligated to date
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

Other recent filings by Rep. Kevin Hern (OK01)

The full history of Rep. Kevin Hern (OK01) is on the profile page.

How this filing works

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data